CDC Home

HIV Infection and HIV-Associated Behaviors Among Injecting Drug Users — 20 Cities, United States, 2009

Despite a recent reduction in the number of human immunodeficiency virus (HIV) infections attributed to injecting drug use in the United States (1), 9% of new U.S. HIV infections in 2009 occurred among injecting drug users (IDUs) (2). To monitor HIV-associated behaviors and HIV prevalence among IDUs, CDC's National HIV Behavioral Surveillance System (NHBS) conducts interviews and HIV testing in selected metropolitan statistical areas (MSAs). This report summarizes data from 10,073 IDUs interviewed and tested in 20 MSAs in 2009. Of IDUs tested, 9% had a positive HIV test result, and 45% of those testing positive were unaware of their infection. Among the 9,565 IDUs with HIV negative or unknown HIV status before the survey, 69% reported having unprotected vaginal sex, 34% reported sharing syringes, and 23% reported having unprotected heterosexual anal sex during the 12 previous months. Although these risk behavior prevalences appear to warrant increased access to HIV testing and prevention services, for the previous 12-month period, only 49% of the IDUs at risk for acquiring HIV infection reported having been tested for HIV, and 19% reported participating in a behavioral intervention. Increased HIV prevention and testing efforts are needed to further reduce HIV infections among IDUs.

NHBS monitors HIV-associated behaviors and HIV prevalence among populations at high risk for acquiring HIV. In 2009, NHBS staff members in 20 MSAs with high prevalence of acquired immunodeficiency syndrome (AIDS)* collected cross-sectional behavioral risk data and conducted HIV testing among IDUs using respondent-driven sampling, a peer-referral sampling method (3,4). Recruitment chains in each city began with one to 15 initial participants recruited by NHBS staff members during formative assessment and planning. Initial participants who completed the interview were asked to recruit up to five other IDUs through use of a coded coupon system designed to track referrals. Recruitment continued for multiple waves; all participation was voluntary. Persons were eligible to participate if they had injected drugs during the previous 12 months, resided in the MSA, and could complete the interview in English or Spanish. After participants gave oral informed consent, in-person interviews were conducted by trained interviewers who administered a standardized, anonymous questionnaire about HIV-associated behaviors. All respondents were offered anonymous HIV testing, which was performed by collecting blood or oral specimens for either rapid testing in the field or laboratory-based testing. A nonreactive rapid test result was considered HIV negative; a reactive rapid test result was considered HIV positive if confirmed by Western blot or indirect immunofluorescence assay. Incentives were offered for participating in the interview, completing an HIV test, and for recruiting IDUs to participate.

For this report, data on HIV testing and 13 HIV-associated behaviors were analyzed. Participants were asked whether, in the previous 12 months, they 1) had shared syringes; 2) had shared injection equipment other than syringes; 3) had vaginal sex; 4) had unprotected vaginal sex; 5) had heterosexual anal sex; 6) had unprotected heterosexual anal sex; 7) had male-male anal sex; 8) had unprotected male-male anal sex; 9) had more than one opposite sex partner; 10) had been tested previously for HIV infection; and 11) had participated in an HIV behavioral intervention. In addition, participants were asked whether they had ever been tested for 12) HIV or 13) hepatitis C virus (HCV) infection.§ IDUs who tested HIV positive during the survey were defined as unaware of their HIV infection if they had reported that their most recent previous HIV test result was negative, indeterminate, or unknown, or that they had never been tested. IDUs with self-reported negative, indeterminate, or unknown status (including those who tested positive during the survey), were considered to be at risk for acquiring HIV. Data from each MSA were analyzed using a respondent-driven sampling analysis tool that produces estimates adjusted for differences in peer recruitment patterns and size of participant IDU peer networks. Results from these analyses were aggregated and weighted by the size of the IDU population in each MSA (5) to obtain estimates overall.

In 2009, a total of 13,186 persons were recruited to participate; of these, 2,687 (20%) were found ineligible. An additional 426 (3%) eligible participants were excluded from analysis.** Data for the remaining 10,073 participants were used in the analysis of HIV prevalence and participant awareness of serostatus (Table 1). To focus the analysis of HIV-associated behaviors on persons at risk for acquiring HIV infection, 508 participants who reported that they previously had tested positive for HIV were excluded (Table 2).

Among 10,073 IDUs, 9% tested positive for HIV. Prevalence of HIV infection was higher among Hispanics (12%) and non-Hispanic blacks (11%) than non-Hispanic whites (6%). IDUs in the Northeast and South regions had higher HIV prevalence (12% and 11%) than those in the Midwest and West regions (5% and 6%). Those with less than a high school education had higher HIV prevalence (13%) than IDUs who completed high school (8%) or had more than high school education (7%) (Table 1). Among HIV-infected IDUs, 45% (95% confidence interval [CI] = 38%–51%) were unaware of their infection.

Among the 9,565 IDUs at risk for acquiring HIV infection and responding to questions regarding HIV-associated behaviors in the previous 12 months, 34% reported sharing syringes, 46% reported multiple opposite sex partners, 69% reported unprotected vaginal sex, and 23% reported unprotected heterosexual anal sex. In addition, 19% reported participating in an HIV behavioral intervention, and 49% reported having had an HIV test (Table 2).

Among the IDUs at risk for acquiring HIV infection, 72% reported ever being tested for HCV infection (Table 2), and 89% (CI = 88%–90%) reported ever having an HIV test. Among male IDUs at risk for acquiring HIV infection, 7% (CI = 5%–8%) reported male-male anal sex in the previous 12 months, and 5% (CI = 3%–7%) reported unprotected male-male anal sex in the previous 12 months.

The prevalence of HIV-associated risk behaviors in the previous 12 months generally decreased with increasing age. For example, among persons aged 18–29 years, 52% reported sharing syringes, compared with 39% aged 30–39 years, 34% aged 40–49 years, and 25% aged ≥50 years. A higher percentage of IDUs with less than a high school education reported sharing syringes (38%), compared with high school graduates (32%) or those with higher education (31%). Lower percentages of IDUs with less than a high school education reported participation in HIV interventions (16%) and testing for HCV infection (67%), compared with those with a high school education (20% and 73%, respectively) and those with higher deducation (24% and 78%, respectively). A higher percentage of those living at or below the federal poverty level (35%) shared syringes than those above the poverty level (27%), and a lower percentage of those living at or below the poverty level had HCV testing (70%) than those above the poverty level (78%) (Table 2).

Reported by

Cyprian Wejnert, PhD, Huong Pham, MPH, Alexandra M. Oster, MD, Elizabeth A. DiNenno, PhD, Amanda Smith, MPH, Nevin Krishna, MS, Amy Lansky, PhD, Div of HIV/AIDS Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, CDC. Corresponding contributor: Cyprian Wejnert, cwejnert@cdc.gov, 404-639-6044.

Editorial Note

The 2009 data in this report provide the first estimates from a large-scale survey of HIV seroprevalence among IDUs since 1993–1997, when CDC conducted anonymous HIV testing among IDUs entering drug treatment centers in 14 MSAs (6). In the study of IDUs entering drug treatment, HIV prevalence was found to be 18% (range by MSA = 1%–37%). In this analysis, 9% of IDUs tested positive for HIV infection. Furthermore, 45% of those testing positive were unaware of their infection.

Risk behavior prevalences in this report showing that IDUs are at risk for acquiring HIV infection through their sexual behavior in addition to their drug use practices are similar to previously reported NHBS surveillance data (7). Compared with a similar analysis of IDUs interviewed during 2005–2006, lower percentages in this 2009 study reported receiving HIV interventions (19% compared with 30%) and HIV testing (49% compared with 66%) in the previous 12 months (7). These results highlight the need for expanded HIV testing and prevention among IDUs. The combination of declining HIV prevalence and high-risk behavior represent a critical intervention opportunity to further reduce HIV prevalence and incidence among IDUs.

Consistent with previous reports (8), this analysis found higher HIV prevalence among Hispanic and non-Hispanic black IDUs than non-Hispanic white IDUs. However, minority IDUs were neither more nor less likely to have received HIV testing, participated in HIV behavioral interventions, or engaged in risk behaviors than white IDUs in the 12 months preceding the NHBS interview. These data suggest factors not assessed by this study might be contributing to racial/ethnic disparities in HIV prevalence among IDUs.

The findings in this report are subject to at least three limitations. First, some participants might not have accurately reported their behavior to interviewers, and results might be affected by social desirability bias. Second, because no method of obtaining probability samples of IDUs exists, the representativeness of the NHBS sample cannot be determined. Although respondent-driven sampling adjusts for some selection biases (4), other biases might have affected the sample. Finally, IDUs were interviewed in 20 MSAs with high AIDS prevalence; findings from these cities might not be generalizable to other cities or states.

To reduce the number of new HIV infections, the National HIV/AIDS Strategy†† calls for intensifying prevention efforts in communities where HIV is most heavily concentrated. CDC's high impact prevention approach§§ is an essential step toward achieving the goals of the national strategy. HIV prevention strategies for IDUs, including HIV testing and linkage to care, prevention and care for HIV-infected IDUs, and access to new sterile syringes,¶¶ have been shown to be effective. Targeted, effective approaches to HIV prevention will help reduce the number of new HIV infections among IDUs.

Acknowledgments

National HIV Behavioral Surveillance System staff members, including Jennifer Taussig, Laura Salazar, Shacara Johnson, Jeff Todd, Atlanta, Georgia; Colin Flynn, Danielle German, Baltimore, Maryland; Debbie Isenberg, Maura Driscoll, Elizabeth Hurwitz, Boston, Massachusetts; Nik Prachand, Nanette Benbow, Chicago, Illinois; Sharon Melville, Richard Yeager, Jim Dyer, Alicia Novoa, Dallas, Texas; Mark Thrun, Alia Al-Tayyib, Denver, Colorado; Emily Higgins, Eve Mokotoff, Detroit, Michigan; Aaron Sayegh, Jan Risser, Hafeez Rehman, Houston, Texas; Trista Bingham, Ekow Sey, Los Angeles, California; Lisa Metsch, Dano Beck, David Forrest, Gabriel Cardenas, Miami, Florida; Chris Nemeth, Lou Smith, Carol-Ann Watson, Nassau-Suffolk, New York; William Robinson, DeAnn Gruber, Narquis Barak, New Orleans, Louisiana; Alan Neaigus, Sam Jenness, Travis Wendel, Camila Gelpi-Acosta, New York, New York; Henry Godette, Barbara Bolden, Sally D'Errico, Newark, New Jersey; Kathleen Brady, Althea Kirkland, Mark Shpaner, Philadelphia, Pennsylvania; Vanessa Miguelino-Keasling, Al Velasco, San Diego, California; Henry Raymond, San Francisco, California; Sandra Miranda De León, Yadira Rolón-Colón, San Juan, Puerto Rico; Maria Courogen, Hanne Thiede, Nadine Snyder, Richard Burt, Seattle, Washington; and Tiffany West-Ojo, Manya Magnus, Irene Kuo, District of Columbia.

References

  1. CDC. Diagnoses of HIV infection and AIDS in the United States: HIV surveillance report, Vol. 21. Atlanta, GA: US Department of Health and Human Services, CDC; 2011. Available at http://www.cdc.gov/hiv/surveillance/resources/reports/2009report/index.htm. Accessed February 24, 2012.
  2. Prejean J, Song R, Hernandez A, et al. Estimated HIV incidence in the United States, 2006–2009. Plos One 2011;6:e17502.
  3. Lansky A, Abdul-Quader AS, Cribbin M, et al. Developing an HIV behavioral surveillance system for injecting drug users: the National HIV Behavioral Surveillance System. Public Health Rep 2007;122(Suppl 1):48–55.
  4. Salganik MJ, Heckathorn DD. Sampling and estimation in hidden populations using respondent-driven sampling. Sociol Method 2004;34:193–240.
  5. Brady JE, Friedman SR, Cooper HL, Flom PL, Tempalski B, Gostnell K. Estimating the prevalence of injection drug users in the U.S. and in large U.S. metropolitan areas from 1992 to 2002. J Urban Health 2008;85:323–51.
  6. CDC. HIV prevalence trends in selected populations in the United States: results from national serosurveillance, 1993–1997. Atlanta, GA: US Department of Health and Human Services, CDC; 2001. Available at http://www.cdc.gov/hiv/topics/testing/resources/reports/hiv_prevalence/index.htm. Accessed February 24, 2012.
  7. CDC. HIV-associated behaviors among injecting-drug users—23 cities, United States, May 2005–February 2006. MMWR 2009;58:329–32.
  8. CDC. HIV surveillance—United States, 1981–2008. MMWR 2011;60:689–93.

* The 20 MSAs were Atlanta, Georgia; Baltimore, Maryland; Boston, Massachusetts; Chicago, Illinois; Dallas, Texas; Denver, Colorado; Detroit, Michigan; Houston, Texas; Los Angeles, California; Miami, Florida; Nassau-Suffolk, New York; New Orleans, Louisiana; New York, New York; Newark, New Jersey; Philadelphia, Pennsylvania; San Diego, California; San Francisco, California; San Juan, Puerto Rico; Seattle, Washington; and Washington, District of Columbia.

The incentive format (cash or gift card) and amount varied by MSA based on formative assessment and local policy. A typical format included $25 for completing the interview, $25 for providing a specimen for HIV testing, and $10 for each successful recruitment (maximum of five).

§ Sharing syringes was defined as "using needles that someone else had already injected with." Sharing injection equipment was defined as using cookers, cottons, or water to rinse needles or prepare drugs "that someone else had already used." Unprotected vaginal and anal sex were defined as "sex without a condom." Male-male anal sex was restricted to males and includes both insertive and receptive anal sex. Participating in an individual or group HIV behavioral intervention (e.g., a one-on-one conversation with a counselor or an organized discussion regarding HIV prevention) did not include counseling received as part of an HIV test. Testing for HCV infection was measured as ever tested or ever received a diagnosis of hepatitis C.

City-level estimates with inadequate sample size for analysis (five or fewer observations) were excluded from aggregation. For city-level estimates for which confidence intervals could not be calculated, maximally wide confidence intervals (0–1) were used in aggregation. Such estimates represented <4% of the analysis.

** Data from 426 participants were excluded because of missing recruitment data (five participants), lost data during electronic upload (142), incomplete survey data (25), survey responses with questionable validity (63), invalid HIV test results (130), could not be identified as male or female (53), or other reason (eight). Reasons for exclusion were not mutually exclusive and were applied hierarchically in the order listed.

†† Additional information available at http://www.whitehouse.gov/administration/eop/onap/nhas.

§§ Additional information available at http://www.cdc.gov/hiv/strategy.

¶¶ In December 2011, Congress reinstated a ban on the use of federal funds for carrying out any program of distributing sterile needles or syringes for hypodermic injection of illegal drugs.


What is already known on this topic?

Injecting drug users (IDUs) in the United States are at increased risk for acquiring human immunodeficiency virus (HIV) infection. Surveys of IDUs entering drug treatment centers during 1993–1997 found local HIV prevalence ranging from 1% to 37% and an overall prevalence of 18%.

What is added by this report?

The National HIV Behavioral Surveillance System recruited 10,073 IDUs from 20 U.S. metropolitan statistical areas to be interviewed and tested for HIV infection in 2009. Nine percent tested positive for HIV, of whom 45% were unaware of their infection. Among those at risk for acquiring HIV infection, 34% reported sharing syringes, and 69% reported having unprotected vaginal sex in the previous 12 months.

What are the implications for public health practice?

Many IDUs are at risk for acquiring HIV infection because of their drug use practices and sexual behaviors, and a substantial percentage of IDUs in urban areas with high HIV prevalence are already infected but unaware of their infection. To prevent infections, IDUs need ready access to HIV testing, new sterile syringes, condoms, and substance abuse treatment.


TABLE 1. Estimated prevalence of human immunodeficiency virus (HIV) infection among injecting drug users (IDUs) (N = 10,073), by selected characteristics — National HIV Behavioral Surveillance System,* United States, 2009

Characteristic

Overall

HIV prevalence

%

(95% CI)

%

(95% CI)

Overall

100

9

(8–11)

Sex

Men

71

(69–73)

9

(8–10)

Women

29

(27–31)

10

(8–13)

Race/Ethnicity

Hispanic

22

(20–25)

12

(9–15)

Black, non-Hispanic

42

(40–44)

11

(10–13)

White, non-Hispanic

31

(29–34)

6

(4–8)

Other§

4

(4–5)

Age group (yrs)

18–29

11

(10–13)

3

(0–10)

30–39

19

(18–21)

10

(6–13)

40–49

32

(30–34)

11

(9–13)

≥50

38

(36–39)

10

(7–12)

Education

Less than high school diploma

36

(34–38)

13

(10–15)

High school diploma

39

(37–41)

8

(6–10)

More than high school diploma

25

(24–27)

7

(5–9)

Poverty level

At or below federal poverty level

81

(80–83)

10

(8–11)

Above federal poverty level

19

(17–20)

7

(4–9)

Drug injected most frequently

Heroin only

64

(62–66)

7

(4–9)

Other/Multiple

36

(34–38)

14

(12–16)

Region**

Northeast

34

(21–48)

12

(9–14)

South

27

(13–40)

11

(9–14)

Midwest

8

(0–22)

5

(2–7)

West

28

(15–42)

6

(4–8)

Abbreviation: CI = confidence interval.

* The National HIV Behavioral Surveillance System covers the following 20 metropolitan statistical areas (MSAs): Atlanta, Georgia; Baltimore, Maryland; Boston, Massachusetts; Chicago, Illinois; Dallas, Texas; Denver, Colorado; Detroit, Michigan; Houston, Texas; Los Angeles, California; Miami, Florida; Nassau-Suffolk, New York; New Orleans, Louisiana; New York, New York; Newark, New Jersey; Philadelphia, Pennsylvania; San Diego, California; San Francisco, California; San Juan, Puerto Rico; Seattle, Washington; and Washington, District of Columbia.

Percentages were weighted to adjust for differences in recruitment, the size of participants' networks of IDUs, and the size of the population of IDUs in each MSA.

§ Includes American Indian/Alaska Natives, Asians, Native Hawaiian or other Pacific Islanders, and persons of multiple races.

Other drugs injected alone or two or more drugs injected with the same frequency.

** The Northeast region includes the MSAs of Boston, Massachusetts; Nassau-Suffolk, New York; New York, New York; Newark, New Jersey; and Philadelphia, Pennsylvania. South region includes Atlanta, Georgia; Baltimore, Maryland; Dallas, Texas; Houston, Texas; Miami, Florida; New Orleans, Louisiana; and Washington, District of Columbia. Midwest region includes Chicago, Illinois and Detroit, Michigan. West region includes Denver, Colorado; Los Angeles, California; San Diego, California; San Francisco, California; and Seattle, Washington. San Juan, Puerto Rico, was not included.


TABLE 2. Estimated percentage* of injecting drug users at risk for acquiring human immunodeficiency virus (HIV) infection (n = 9,565) who engaged in behaviors§ associated with HIV infection, by selected characteristics — National HIV Behavioral Surveillance System, United States, 2009

Characteristic

Shared syringes

Shared injection equipment

Had vaginal sex

Had unprotected vaginal sex

Had heterosexual anal sex

Had unprotected heterosexual anal sex

Had more than one opposite sex partner

Was tested for HIV infection

Participated in behavioral intervention

Was ever tested for hepatitis C**

(95% CI)

(95% CI)

(95% CI)

(95% CI)

(95% CI)

(95% CI)

(95% CI)

(95% CI)

(95% CI)

(95% CI)

Overall

34

58

80

69

29

23

46

49

19

72

(32–36)

(56–60)

(78–82)

(67–71)

(27–31)

(21–24)

(44–48)

(47–51)

(18–21)

(70–74)

Sex

Men

32

57

79

67

29

23

45

47

18

71

(30–34)

(54–59)

(77–81)

(65–69)

(27–31)

(21–25)

(43–48)

(45–50)

(17–20)

(69–73)

Women

38

60

81

73

28

22

47

52

22

73

(35–42)

(57–64)

(79–84)

(70–76)

(25–31)

(20–25)

(43–50)

(48–55)

(19–25)

(70–77)

Race/Ethnicity

Hispanic

34

59

81

67

40

31

45

48

17

71

(30–38)

(55–63)

(78–85)

(62–71)

(35–44)

(27–35)

(40–50)

(44–53)

(13–20)

(67–75)

Black, non-Hispanic

27

54

81

69

24

19

47

52

21

67

(24–29)

(51–57)

(79–84)

(67–72)

(22–27)

(17–21)

(44–50)

(49–54)

(18–23)

(64–70)

White, non-Hispanic

43

62

80

72

29

23

45

44

20

78

(39–47)

(58–66)

(76–83)

(68–76)

(26–32)

(20–26)

(42–49)

(40–48)

(17–22)

(74–81)

Other††

40

58

71

59

23

16

47

52

18

80

(31–50)

(50–67)

(61–80)

(50–67)

(16–30)

(11–21)

(39–56)

(43–61)

(13–23)

(72–87)

Age group (yrs)

18–29

52

73

92

83

44

35

62

52

23

70

(47–57)

(69–78)

(88–97)

(79–88)

(38–49)

(30–40)

(57–67)

(46–58)

(18–27)

(65–75)

30–39

39

64

88

79

41

35

51

48

19

72

(34–44)

(60–68)

(85–91)

(75–83)

(37–45)

(30–39)

(46–56)

(43–53)

(16–23)

(67–76)

40–49

34

55

79

69

28

22

45

54

19

71

(31–38)

(52–59)

(76–82)

(65–72)

(25–31)

(19–25)

(41–48)

(51–58)

(16–22)

(68–75)

≥50

25

52

72

59

19

14

39

43

19

73

(23–28)

(49–55)

(70–75)

(56–62)

(16–21)

(12–15)

(36–42)

(40–46)

(16–22)

(70–76)

Education

Less than high school diploma

38

59

81

69

32

26

47

47

16

67

(35–42)

(56–62)

(78–83)

(67–72)

(29–35)

(23–29)

(43–50)

(43–50)

(14–18)

(63–70)

High school diploma

32

57

79

68

27

21

43

50

20

73

(30–35)

(54–60)

(76–82)

(65–71)

(24–30)

(19–23)

(40–46)

(47–53)

(18–23)

(70–75)

More than high school diploma

31

57

81

69

28

22

49

49

24

78

(27–35)

(53–61)

(78–84)

(66–73)

(24–31)

(18–25)

(46–53)

(45–53)

(20–27)

(74–81)

Poverty level

At or below federal poverty level

35

58

80

68

28

22

46

48

20

70

(33–38)

(56–60)

(78–82)

(66–70)

(26–30)

(20–24)

(43–49)

(46–50)

(18–22)

(68–72)

Above federal poverty level

27

55

81

71

30

24

43

52

18

78

(23–31)

(51–59)

(77–85)

(67–75)

(26–34)

(21–28)

(39–48)

(48–57)

(15–21)

(75–82)


TABLE 2. (Continued) Estimated percentage* of injecting drug users at risk for acquiring human immunodeficiency virus (HIV) infection (n = 9,565) who engaged in behaviors§ associated with HIV infection, by selected characteristics — National HIV Behavioral Surveillance System, United States, 2009

Characteristic

Shared syringes

Shared injection equipment

Had vaginal sex

Had unprotected vaginal sex

Had heterosexual anal sex

Had unprotected heterosexual anal sex

Had more than one opposite sex partner

Was tested for HIV infection

Participated in behavioral intervention

Was ever tested for hepatitis C**

(95% CI)

(95% CI)

(95% CI)

(95% CI)

(95% CI)

(95% CI)

(95% CI)

(95% CI)

(95% CI)

(95% CI)

Drug injected most frequently

Heroin only

33

57

78

66

25

20

42

47

19

73

(30–35)

(54–59)

(76–81)

(64–69)

(23–27)

(18–22)

(39–44)

(45–50)

(17–21)

(70–75)

Other/Multiple§§

36

60

83

74

35

27

53

51

21

70

(33–39)

(57–63)

(80–86)

(71–77)

(32–38)

(24–30)

(50–56)

(48–55)

(18–23)

(67–73)

Region¶¶

Northeast

35

55

82

71

34

27

46

51

22

74

(32–39)

(51–59)

(78–85)

(67–75)

(30–37)

(24–30)

(42–50)

(47–55)

(19–25)

(71–78)

South

33

62

84

73

26

20

48

53

21

68

(30–37)

(59–65)

(82–86)

(70–76)

(23–29)

(17–23)

(44–51)

(50–56)

(18–24)

(64–71)

Midwest

26

44

80

62

24

17

48

41

11

59

(22–31)

(39–49)

(76–85)

(57–67)

(20–28)

(13–20)

(43–53)

(37–46)

(8–14)

(54–64)

West

35

61

74

64

26

20

43

45

16

77

(32–39)

(57–65)

(70–78)

(60–68)

(22–29)

(17–24)

(39–47)

(40–49)

(13–19)

(73–81)

Abbreviation: CI = confidence interval.

* Percentages were weighted to adjust for differences in recruitment, the size of participants' networks of IDUs, and the size of the population of IDUs in each metropolitan statistical area (MSA).

IDUs at risk for acquiring HIV infection were defined as those reporting having never had an HIV test or that their most recent HIV test result was negative, indeterminate, or unknown. This group includes those IDUs who did not know they were HIV positive before the interview but tested positive during the interview.

§ Sharing syringes was defined as "using needles that someone else had already injected with," and sharing injection equipment was defined as using equipment such as cookers, cottons, or water used to rinse needles or prepare drugs "that someone else had already used." Unprotected vaginal sex/Unprotected anal sex was defined as "sex without a condom." Participating in an individual or group HIV behavioral intervention (e.g., a one-on-one conversation with a counselor or an organized discussion regarding HIV prevention) did not include counseling received as part of an HIV test.

The National HIV Behavioral Surveillance System covers the following MSAs: Atlanta, Georgia; Baltimore, Maryland; Boston, Massachusetts; Chicago, Illinois; Dallas, Texas; Denver, Colorado; Detroit, Michigan; Houston, Texas; Los Angeles, California; Miami, Florida; Nassau-Suffolk, New York; New Orleans, Louisiana; New York, New York; Newark, New Jersey; Philadelphia, Pennsylvania; San Diego, California; San Francisco, California; San Juan, Puerto Rico; Seattle, Washington; and Washington, District of Columbia.

** Testing for hepatitis C virus infection was measured as ever tested or ever received a diagnosis of hepatitis C. All other behaviors are reported for the previous 12 months.

†† Includes American Indian/Alaska Natives, Asians, Native Hawaiian or other Pacific Islanders, and persons of multiple races.

§§ Other drugs injected alone or two or more drugs injected with the same frequency.

¶¶ The Northeast region includes the MSAs of Boston, Massachusetts; Nassau-Suffolk, New York; New York, New York; Newark, New Jersey; and Philadelphia, Pennsylvania. South region includes Atlanta, Georgia; Baltimore, Maryland; Dallas, Texas; Houston, Texas; Miami, Florida; New Orleans, Louisiana; and Washington, District of Columbia. Midwest region includes Chicago, Illinois and Detroit, Michigan. West region includes Denver, Colorado; Los Angeles, California; San Diego, California; San Francisco, California; and Seattle, Washington. San Juan, Puerto Rico, was not included.


Use of trade names and commercial sources is for identification only and does not imply endorsement by the U.S. Department of Health and Human Services.

References to non-CDC sites on the Internet are provided as a service to MMWR readers and do not constitute or imply endorsement of these organizations or their programs by CDC or the U.S. Department of Health and Human Services. CDC is not responsible for the content of pages found at these sites. URL addresses listed in MMWR were current as of the date of publication.

All MMWR HTML versions of articles are electronic conversions from typeset documents. This conversion might result in character translation or format errors in the HTML version. Users are referred to the electronic PDF version (http://www.cdc.gov/mmwr) and/or the original MMWR paper copy for printable versions of official text, figures, and tables. An original paper copy of this issue can be obtained from the Superintendent of Documents, U.S. Government Printing Office (GPO), Washington, DC 20402-9371; telephone: (202) 512-1800. Contact GPO for current prices.

**Questions or messages regarding errors in formatting should be addressed to mmwrq@cdc.gov.

 
USA.gov: The U.S. Government's Official Web PortalDepartment of Health and Human Services
Centers for Disease Control and Prevention   1600 Clifton Rd. Atlanta, GA 30333, USA
800-CDC-INFO (800-232-4636) TTY: (888) 232-6348 - Contact CDC–INFO
A-Z Index
  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z
  27. #